- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04562883
Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes
Effect of Single vs. Group CAPA-IVM Culture of Human Cumulus-oocyte Complexes From Small Antral Follicles in a SIBLING Oocyte Study Design
Study Overview
Status
Intervention / Treatment
Detailed Description
Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART.
Oocytes retrieved for IVM procedures derive from a heterogeneous pool with variable cellular and molecular characteristics that indicate its immature status. Thus, in vitro systems that permit and enhance acquisition and synchronization of meiotic competence (ability to resume meiosis in response to an ovulatory stimulus) and developmental competence (ability to be fertilized and support early embryo development) before the meiotic trigger are crucial for the optimization of human IVM systems.
A novel two-step IVM culture system (named CAPA-IVM) involving a pre-maturation culture with C-type natriuretic peptide (CNP) and a maturation step in presence of Amphiregulin (AREG), both more physiological compounds improving oocyte competence, have been introduced in previous clinical studies. So far these pilot studies proved to increase the rates of oocyte maturation, good quality embryos on day 3, good quality blastocyst, and as a result a higher embryo yield. CAPA-IVM blastocysts have shown similar rates of methylation and gene expression at gDMRs compared to COS embryos; and the expression of ma-jor epigenetic regulators was similar between both groups. Furthermore, an improvement in pregnancy rates strengthens the clinical relevance of the use of CAPA-IVM strategy.
In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM. A single COC culture would permit to perform a non-invasive molecular analysis per matured oocyte, in order to identify quality genes ex-pressed in cumulus cells post-IVM (cumulus biomarkers), which could be subsequently used to identify the embryo(s) with highest potential of implantation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ho Chi Minh City, Vietnam
- My Duc Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (>10ml) (it is sufficient that 1 ovary fits these criteria)
- No major uterine or ovarian abnormalities
- Having at least 15 follicles on the OPU day
- Patients consent to participate in the study
Exclusion Criteria:
- High (>grade 2) grade endometriosis
- Cases with extremely poor sperm (serve OAT: density <1 million, mobility <10% and sperm from testicular surgery)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Culture
Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the "washing dish" containing "Maturation Medium" and wash them thoroughly.
Then transfer COCs one by one to the "Culture dish" with "Maturation Medium".
|
Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation.
The first group will be culture in pools (group culture).
The second group will be culture individually in 20µl droplets.
|
Experimental: Group Culture
Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the "washing dish" containing "Maturation Medium (Group Culture)" by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max.
10µl).
Then transfer COCs to the "IVM dish" with "Maturation Medium (Group Culture)".
|
Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation.
The first group will be culture in pools (group culture).
The second group will be culture individually in 20µl droplets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of good quality embryos
Time Frame: At least 3 days after intra-cytoplasmic sperm injection
|
Number of good quality Day 3 embryos obtained
|
At least 3 days after intra-cytoplasmic sperm injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Multiple delivery
Time Frame: At 24 weeks' gestation
|
Birth of more than one baby beyond 24 weeks
|
At 24 weeks' gestation
|
Maturation rate
Time Frame: Two days after oocytes pick-up
|
Percentage of mature oocytes by 2 types of COC culture
|
Two days after oocytes pick-up
|
Fertilization rate
Time Frame: 16-18 hours after intra-cytoplasmic sperm injection
|
Percentage of fertilized oocytes by 2 types of COC culture
|
16-18 hours after intra-cytoplasmic sperm injection
|
Cleavage rate
Time Frame: At least 3 days after intra-cytoplasmic sperm injection
|
Percentage of day-3 embryos over fertilized oocytes by 2 types of COC culture
|
At least 3 days after intra-cytoplasmic sperm injection
|
Expansion rate
Time Frame: After at least 30 hours of maturation culture
|
Percentage of cumulus-oocyte complexes expanded after culture by 2 types of COC culture
|
After at least 30 hours of maturation culture
|
The relative expression ratio ( R ) of human cumulus cell genes
Time Frame: cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification
|
Cumulus cells will be collected, cDNA synthesis after mRNA purification, relative quantification PCR for detecting gene expression
|
cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification
|
Clinical pregnancy
Time Frame: 5 weeks after embryo placement after the completion of the first transfer
|
at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity
|
5 weeks after embryo placement after the completion of the first transfer
|
Implantation rate
Time Frame: 3 weeks after embryo transferred after the completion of the first transfer
|
as the number of gestational sacs per number of embryos transferred
|
3 weeks after embryo transferred after the completion of the first transfer
|
Ongoing pregnancy
Time Frame: At 12 weeks' gestation
|
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer
|
At 12 weeks' gestation
|
Miscarriage
Time Frame: at 24 weeks of gestation after the completion of the first transfer
|
pregnancy loss at < 24 weeks
|
at 24 weeks of gestation after the completion of the first transfer
|
Multiple pregnancy
Time Frame: 5 weeks after embryo placement after the completion of the first transfer
|
Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)
|
5 weeks after embryo placement after the completion of the first transfer
|
Positive pregnancy test
Time Frame: at 2 weeks after the embryo placement after the completion of the first transfer
|
Serum human chorionic gonadotropin level greater than 25 mIU/mL
|
at 2 weeks after the embryo placement after the completion of the first transfer
|
Live birth
Time Frame: At 24 weeks of gestation
|
defined as at least one newborn after 24 weeks of gestation and exhibiting any sign of life; twins were counted as a single birth
|
At 24 weeks of gestation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tuong M Ho, MD, MCE, Hope Research Center
Publications and helpful links
General Publications
- Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.
- Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4.
- Sanchez F, Romero S, De Vos M, Verheyen G, Smitz J. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum Reprod. 2015 Jun;30(6):1396-409. doi: 10.1093/humrep/dev083. Epub 2015 Apr 22.
- Saenz-de-Juano MD, Ivanova E, Billooye K, Herta AC, Smitz J, Kelsey G, Anckaert E. Genome-wide assessment of DNA methylation in mouse oocytes reveals effects associated with in vitro growth, superovulation, and sexual maturity. Clin Epigenetics. 2019 Dec 19;11(1):197. doi: 10.1186/s13148-019-0794-y. Erratum In: Clin Epigenetics. 2020 Jan 27;12(1):18.
- Sanchez F, Lolicato F, Romero S, De Vos M, Van Ranst H, Verheyen G, Anckaert E, Smitz JEJ. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017 Oct 1;32(10):2056-2068. doi: 10.1093/humrep/dex262.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13/20/DD-BVMD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PCOS
-
University Of PerugiaRecruiting
-
Guangdong Women and Children HospitalRecruiting
-
Khyber Medical University PeshawarCompleted
-
AdventHealth Translational Research InstituteActive, not recruiting
-
Ain Shams Maternity HospitalUnknown
-
Children's Mercy Hospital Kansas CityCompleted
-
Poznan University of Medical SciencesUniversity of California, San DiegoUnknown
-
University of SalernoTheoreo SrlCompleted
-
Genesis Center for Fertility & Human Pre-Implantation...Unknown
Clinical Trials on The way of Cumulus-oocyte complexes (COC) culture
-
Mỹ Đức HospitalRecruitingIVM | PCOS (Polycystic Ovary Syndrome)Vietnam